Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://link.springer.com/chapter/10.1007/978-1-4614-4732-0_12, but it redirected us to https://link.springer.com/chapter/10.1007/978-1-4614-4732-0_12. The analysis below is for the second page.

Title[redir]:
Targeted Toxins in Cancer Immunotherapy | SpringerLink
Description:
Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has...

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is doi.org built with?


Doi.org uses VBULLETIN.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don’t know how the website earns money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

google, scholar, pubmed, cas, article, cancer, clin, res, phase, immunotoxin, patients, lymphoma, study, recombinant, targeted, treatment, oncol, therapy, antibody, ther, nat, cells, kreitman, leukemia, pastan, chapter, curiel, ricin, blood, bcell, immunotoxins, targeting, med, mol, human, anticd, immunoconjugate, immunotherapy, rev, immunol, clinical, refractory, cell, receptor, interleukin, phd, tumor, toxin, conjugate, delivery,

Topics {✒️}

maytansinoid immunoconjugate hun901-n2'-deacetyl-n2' anti-cd22 immunotoxin igg-rfb4-smpt-dga peptide-linked anti-cd30-auristatin conjugates maytansinoid immunoconjugate b-b4-dm1 anti-cd33 antibody-maytansinoid conjugate anti-cd70 antibody-drug conjugates anti-cd19 immunotoxin b43-pap immunotoxins igg-hd37-deglycosylated ricin anti-cd20-auristatin conjugates targeting il-13ralpha2-positive cancer chemotherapy-resistant hairy-cell leukemia anti-cd22-deglycosylated ricin ricin-monoclonal antibody conjugates igg-anti-cd22 immunotoxins carcinoembryonic antigen-positive tumors month download article/chapter anti-cd22-calecheamicin conjugate targeted toxin tf-crm107 replication-competent retroviral vectors ricin a-chain immunotoxins t-cell antigen receptor anti-breast cancer immunotoxin triantennary n-linked oligosaccharides lynch tj jr immunotoxin n901-blocked ricin antibody-mediated targeted delivery recombinant immunotoxin anti-tac multi-mechanistic therapeutic class anticancer carrier-linked prodrugs toxin–recombinant immunotoxins constructed prostate-specific membrane antigen cd22-targeted cytotoxic immunoconjugate single-chain immunotoxin sgn-10 relapsed cd30-positive lymphomas toxin-based targeted therapy adenoviral vector-based strategies relapsed/refractory b-cell her2-positive breast cancer pretreated b-cell lymphoma b-cell lymphomas resistant small-cell lung cancer monoclonal antibody-ricin single-chain antibody cutaneous t-cell lymphoma cd4+cd25+ human regulatory recurrent b-cell lymphoma vaccine-mediated antitumor immunity prior her2-directed therapy single-chain immunotoxin antibody phage display

Questions {❓}

  • Awada A, Bozovic-Spasojevic I, Chow L (2012) New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Schema {🗺️}

ScholarlyArticle:
      headline:Targeted Toxins in Cancer Immunotherapy
      pageEnd:396
      pageStart:377
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-4614-4732-0.jpg
      genre:
         Biomedical and Life Sciences
         Biomedical and Life Sciences (R0)
      isPartOf:
         name:Cancer Immunotherapy
         isbn:
            978-1-4614-4732-0
            978-1-4614-4731-3
         type:Book
      publisher:
         name:Springer New York
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Devalingam Mahalingam
            affiliation:
                  name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
                  address:
                     name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael J. Brumlik
            affiliation:
                  name:SA Scientific, Ltd
                  address:
                     name:SA Scientific, Ltd, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Reinhard Waehler
            affiliation:
                  name:Washington University School of Medicine
                  address:
                     name:Radiation and Cancer Biology Division, Washington University School of Medicine, St. Louis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David T. Curiel
            affiliation:
                  name:Washington University School of Medicine
                  address:
                     name:Radiation and Cancer Biology Division, Washington University School of Medicine, St. Louis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tyler J. Curiel
            affiliation:
                  name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
                  address:
                     name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:Acute Myeloid Leukemia, Anaplastic Large Cell Lymphoma, Gemtuzumab Ozogamicin, Bispecific Antibody, Brentuximab Vedotin
      description:Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This chapter will summarize the current agents and strategies that exploit immune principles and reagents to develop targeting specificity to treat cancers with maximum sparing of normal tissues.
      datePublished:2013
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Cancer Immunotherapy
      isbn:
         978-1-4614-4732-0
         978-1-4614-4731-3
Organization:
      name:Springer New York
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
      address:
         name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
         type:PostalAddress
      name:SA Scientific, Ltd
      address:
         name:SA Scientific, Ltd, San Antonio, USA
         type:PostalAddress
      name:Washington University School of Medicine
      address:
         name:Radiation and Cancer Biology Division, Washington University School of Medicine, St. Louis, USA
         type:PostalAddress
      name:Washington University School of Medicine
      address:
         name:Radiation and Cancer Biology Division, Washington University School of Medicine, St. Louis, USA
         type:PostalAddress
      name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
      address:
         name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Devalingam Mahalingam
      affiliation:
            name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
            address:
               name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Michael J. Brumlik
      affiliation:
            name:SA Scientific, Ltd
            address:
               name:SA Scientific, Ltd, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Reinhard Waehler
      affiliation:
            name:Washington University School of Medicine
            address:
               name:Radiation and Cancer Biology Division, Washington University School of Medicine, St. Louis, USA
               type:PostalAddress
            type:Organization
      name:David T. Curiel
      affiliation:
            name:Washington University School of Medicine
            address:
               name:Radiation and Cancer Biology Division, Washington University School of Medicine, St. Louis, USA
               type:PostalAddress
            type:Organization
      name:Tyler J. Curiel
      affiliation:
            name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
            address:
               name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
      name:SA Scientific, Ltd, San Antonio, USA
      name:Radiation and Cancer Biology Division, Washington University School of Medicine, St. Louis, USA
      name:Radiation and Cancer Biology Division, Washington University School of Medicine, St. Louis, USA
      name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(519)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Pbgrd

5.14s.